Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022
02 août 2022 15h30 HE
|
Athira Pharma, Inc.
Fosgo-AM, the active metabolite of Fosgonimeton (ATH-1017), demonstrates neuroprotective effects in primary neuron culturesNew orally available small molecule positive modulators of HGF/MET reverse...
Athira Pharma to Present Clinical and Preclinical Data at Alzheimer’s Association International Conference 2022
25 juil. 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., July 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
22 juin 2022 07h00 HE
|
Athira Pharma, Inc.
Primary endpoint of change in biomarker ERP P300 latency was not statistically significant for the full study population as combination of fosgonimeton and standard-of-care (AChEIs) given together...
Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
07 juin 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., June 07, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
19 mai 2022 12h06 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
16 mai 2022 16h49 HE
|
Athira Pharma, Inc.
Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16,...
Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
16 mai 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
12 mai 2022 16h05 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 12, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
11 mai 2022 16h15 HE
|
Athira Pharma, Inc.
Urges Shareholders to Vote TODAY “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May ...
Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
09 mai 2022 07h00 HE
|
Athira Pharma, Inc.
– Study duration increased from 6 months to 18 months of open label treatment with fosgonimeton – BOTHELL, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late...